Browse drugs

…s of disease, with contemporary randomised data emerging in the osimertinib era and ongoing trials addressing optimal timing and completene…

…djusting for relevant covariates.Results Among 8510 adults with cotinine-verified smoking (6754 males; 1756 females), false reporting prevalence …

… therapy with atezolizumab, an immune checkpoint inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor. Three d…

…e dual-payload ADC with immune checkpoint inhibitors (PD-L1 and 4–1BB) not only rapidly bridges innate and adaptive immunity but also…

…atients, with durable responses to combination regimens such as atezolizumab plus bevacizumab occurring in a minority.1 2 Neutrophils, long …

…As nicotine pouches have exploded in popularity, a parallel market of ‘ener…

…d. Immunosuppressive therapy with high-dose corticosteroids and azathioprine was initiated, leading to a gradual improvement of the encephal…

…es induction chemotherapy, including dose-reduced pegaspargase (PEG-Asp), blinatumomab consolidative therapy and HSCT for post-inductio…

…nalyses key ethical arguments brought forward for rejecting the MDMA-AT application. While acknowledging the importance of the ethical …

…programming and is instrumental in shaping the TME. Focusing on lactate and lactylation modifications has been shown to markedly improv…

…s (ECP) two treatments every month, bexarotene 150 mg daily and peginterferon alfa-2 36 ug weekly. Following 7 months of treatment (12 ECP sessions)…

…and interfere with surgical conditions. High-flow nasal oxygen (HFNO) has emerged as a promising alternative for maintaining oxygena…